Control of human mesothelin-expressing tumors by DNA vaccines.
about
Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancerHigh mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinomaAntigen-specific immunotherapy of cervical and ovarian cancerA novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapyThe human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53.PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors.Mesothelin-targeted agents in clinical trials and in preclinical development.Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer.Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and -independent signal pathwayTargeted coating with antigenic peptide renders tumor cells susceptible to CD8(+) T cell-mediated killingIntravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic canceralpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumorsCombined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.Potential targets for pancreatic cancer immunotherapeutics.Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator.Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.Development of anti-human mesothelin-targeted chimeric antigen receptor (CAR) messenger RNA (mRNA)-transfected peripheral blood lymphocytes (CARMA-hMeso) for ovarian cancer therapy.Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells.Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.
P2860
Q24642374-7F35ADFC-87CA-42DF-B3DA-6934D8BB0565Q24651062-E4845A98-7C7B-456A-AF9C-D6833F7F58DDQ24658024-F4579F3F-CD2F-40F6-9356-44593950B44CQ27488697-BD290548-E610-4278-A99E-B5031522BA54Q30478956-B2F20719-27AA-4E4C-AC14-16C9FB0A3354Q33753431-BF40D538-CA3B-4256-9F42-B6CC4C528C23Q34103645-2EE86CD7-78BB-47D1-B310-9D70B2BBCFC1Q34607207-A164F618-F90E-432F-BAB9-43CCADECAC30Q35107110-C3036857-6F10-4171-BBA5-5CC47A52390BQ35185032-4F911A20-E4BD-45AB-ADB9-46F3192FD930Q35815380-4BA22470-52DD-48FA-BD50-8FDD2D8CE584Q36639456-1A0AB5E0-6797-449D-9974-39B429C76E1FQ36649265-4C2CF79E-2484-49AC-8971-EAB69146F383Q36659265-72A8AAF1-7C45-4224-826A-69EB1BC832ECQ36857863-D0760C34-DEA6-460E-882F-077687977C06Q37002097-4246BF8F-C5F6-46CA-84A6-FAC63893E662Q37368087-881DF629-378C-4936-9839-A6EA64688C88Q37659577-11DF291F-9421-476F-BE46-01C44C2F56C8Q37817035-9509C710-DB62-4B8E-B791-98B6DD686C7CQ37861220-E6D13FE9-E542-4C5F-9BE4-A0520151DA0AQ38844559-1F7AEB24-0AE8-40DF-A972-283FF7CB1C21Q39028976-33EA5AA9-323F-4D65-A3BD-8BE620BAC560Q50025535-00BB979F-A30C-4C4C-9984-C60FA3CF1FE4Q53581193-8169AC8D-8534-4FD0-958C-5E14FB8174DAQ55001866-3E016FE0-BB89-485A-BED6-02405746E4DD
P2860
Control of human mesothelin-expressing tumors by DNA vaccines.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Control of human mesothelin-expressing tumors by DNA vaccines.
@ast
Control of human mesothelin-expressing tumors by DNA vaccines.
@en
type
label
Control of human mesothelin-expressing tumors by DNA vaccines.
@ast
Control of human mesothelin-expressing tumors by DNA vaccines.
@en
prefLabel
Control of human mesothelin-expressing tumors by DNA vaccines.
@ast
Control of human mesothelin-expressing tumors by DNA vaccines.
@en
P2093
P2860
P356
P1433
P1476
Control of human mesothelin-expressing tumors by DNA vaccines.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3302974
P577
2007-06-21T00:00:00Z